The Business Of Biotech Podcast
-
Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
3/20/2026
On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma.
-
Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
3/11/2026
On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq.
-
Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.
3/5/2026
On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts.
-
Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.
2/25/2026
On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics.
-
An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.
2/19/2026
On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization.
-
Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer
2/12/2026
On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases.
-
Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie
2/6/2026
On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies.
-
BoB@JPM: Brian Hilberdink, Boehringer Ingelheim
1/29/2026
On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, following his departure from LEO Pharma.
-
BoB@JPM: Ron Cooper, enGene
1/21/2026
On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders.
-
BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics
1/15/2026
The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials.